Vancouver, British Columbia–(Newsfile Corp. – September 9, 2021) – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic” or the “Company“) a Company commercializing a dedicated Breast CT (computed tomography) imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers, announced today that it received a semifinalist nomination for AuntMinnie.com‘s 2021 award campaign to recognize the best and brightest in medical imaging.
Auntminnie.com, a leading radiology news website, has recognized Izotropic’s IzoView Breast CT System in the Best New Radiology Device category. The Company congratulates all other nominees, as it is an honor to be considered for this award.
Izotropic thanks all of those who have worked on and continue to work on IzoView Breast CT and attributes this nomination to everyone’s passion and commitment to improving the outcomes of women’s breast cancer.
Izotropic is the only publicly traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic’s initial clinical study, scheduled to begin in Q2 2022, intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures. In follow-on clinical studies, Izotropic intends to validate platform applications, including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.
IzoView (currently in development) produces high resolution breast images in true 3D and is ideal for imaging patients with dense breast tissue. A single 10 second scan acquires approximately 500 images without painful breast compression or continual technician breast handling, providing a more comfortable patient experience with low radiation dose levels.
In addition to improved detection capabilities, Izotropic anticipates IzoView’s higher resolution 3D images could provide more accurate margin analysis (viewing edges of a tumor), lesion characterization (determining the qualities of an abnormality), and higher spatial resolution (the imaging ability to differentiate between internal breast structures). More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.
ON BEHALF OF THE COMPANY
Dr. John McGraw, CEO
For investor relations inquiries, contact:
James Berard, Investor Relations Manager
Toll Free: 1-833-IZOCORP ext.1
This document may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions, projections and expectations of the Company’s management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company’s activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/95976